Chromadex (NASDAQ:CDXC) Given Coverage Optimism Score of -0.02

News coverage about Chromadex (NASDAQ:CDXC) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chromadex earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 41.8144179808826 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Shares of Chromadex (NASDAQ CDXC) traded down $0.09 during mid-day trading on Wednesday, hitting $5.23. The stock had a trading volume of 378,190 shares, compared to its average volume of 572,393. The company has a quick ratio of 4.12, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $259.50, a PE ratio of -37.35 and a beta of 1.03. Chromadex has a 12 month low of $2.26 and a 12 month high of $7.24.

A number of analysts have weighed in on CDXC shares. BidaskClub cut Chromadex from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Zacks Investment Research cut Chromadex from a “buy” rating to a “hold” rating in a research report on Wednesday, November 29th. HC Wainwright set a $8.00 price target on Chromadex and gave the company a “buy” rating in a research report on Friday, December 15th. Finally, ValuEngine cut Chromadex from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $7.50.

In other Chromadex news, major shareholder River Ventures Ltd Champion bought 731,707 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were bought at an average price of $4.10 per share, for a total transaction of $2,999,998.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $6.19, for a total value of $361,496.00. The disclosure for this sale can be found here. 11.59% of the stock is currently owned by corporate insiders.

WARNING: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Insider Buying and Selling by Quarter for Chromadex (NASDAQ:CDXC)

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with's FREE daily email newsletter.

Leave a Reply